Literature DB >> 10027415

Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice.

J P Theurillat1, J Hainfellner, A Maddalena, J Weissenberger, A Aguzzi.   

Abstract

Angiogenesis is a prerequisite for solid tumor growth. Glioblastoma multiforme, the most common malignant brain tumor, is characterized by extensive vascular proliferation. We previously showed that transgenic mice expressing a GFAP-v-src fusion gene in astrocytes develop low-grade astrocytomas that progressively evolve into hypervascularized glioblastomas. Here, we examined whether tumor progression triggers angiogenetic signals. We found abundant transcription of vascular endothelial growth factor (VEGF) in neoplastic astrocytes at surprisingly early stages of tumorigenesis. VEGF and v-src expression patterns were not identical, suggesting that VEGF activation was not only dependent on v-src. Late-stage gliomas showed perinecrotic VEGF up-regulation similarly to human glioblastoma. Expression patterns of the endothelial angiogenic receptors flt-1, flk-1, tie-1, and tie-2 were similar to those described in human gliomas, but flt-1 was expressed also in neoplastic astrocytes, suggesting an autocrine role in tumor growth. In crossbreeding experiments, hemizygous ablation of the tumor suppressor genes Rb and p53 had no significant effect on the expression of VEGF, flt-1, flk-1, tie-1, and tie-2. Therefore, expression of angiogenic signals is an early event during progression of GFAP-v-src tumors and precedes hypervascularization. Given the close similarities in the progression pattern between GFAP-v-src and human gliomas, the present results suggest that these mice may provide a useful tool for antiangiogenic therapy research.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10027415      PMCID: PMC1849997          DOI: 10.1016/S0002-9440(10)65303-5

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  53 in total

1.  Addressing tumor blood vessels.

Authors:  J Folkman
Journal:  Nat Biotechnol       Date:  1997-06       Impact factor: 54.908

2.  Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas.

Authors:  E Hatva; T Böhling; J Jääskeläinen; M G Persico; M Haltia; K Alitalo
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

3.  Induction of angiogenesis during the transition from hyperplasia to neoplasia.

Authors:  J Folkman; K Watson; D Ingber; D Hanahan
Journal:  Nature       Date:  1989-05-04       Impact factor: 49.962

Review 4.  Angiogenesis in embryos and ischemic diseases.

Authors:  G Breier; A Damert; K H Plate; W Risau
Journal:  Thromb Haemost       Date:  1997-07       Impact factor: 5.249

5.  Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes.

Authors:  D Hanahan
Journal:  Nature       Date:  1985 May 9-15       Impact factor: 49.962

6.  Bovine papillomavirus genome elicits skin tumours in transgenic mice.

Authors:  M Lacey; S Alpert; D Hanahan
Journal:  Nature       Date:  1986 Aug 14-20       Impact factor: 49.962

7.  Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression.

Authors:  N M Mazure; E Y Chen; P Yeh; K R Laderoute; A J Giaccia
Journal:  Cancer Res       Date:  1996-08-01       Impact factor: 12.701

8.  Cell-heritable stages of tumor progression in transgenic mice harboring the bovine papillomavirus type 1 genome.

Authors:  M Sippola-Thiele; D Hanahan; P M Howley
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

9.  Grading of astrocytomas. A simple and reproducible method.

Authors:  C Daumas-Duport; B Scheithauer; J O'Fallon; P Kelly
Journal:  Cancer       Date:  1988-11-15       Impact factor: 6.860

10.  Sequence of a cDNA clone encoding mouse glial fibrillary acidic protein: structural conservation of intermediate filaments.

Authors:  S A Lewis; J M Balcarek; V Krek; M Shelanski; N J Cowan
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

View more
  10 in total

1.  Mouse astrocytoma models: embryonic stem cell mediated transgenesis.

Authors:  H Ding; A Guha
Journal:  J Neurooncol       Date:  2001-07       Impact factor: 4.130

Review 2.  Angiogenesis in transgenic models of multistep carcinogenesis.

Authors:  M G D' Angelo; T Afanasieva; A Aguzzi
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

Review 3.  Molecular mechanisms of tumor angiogenesis and tumor progression.

Authors:  U Cavallaro; G Christofori
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

4.  Distinct and opposite roles for SH2 and SH3 domains of v-src in embryo survival and hemangiosarcoma formation.

Authors:  John C Morgan; John E Majors; Deni S Galileo
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

Review 5.  Genetically engineered mouse models in cancer research.

Authors:  Jessica C Walrath; Jessica J Hawes; Terry Van Dyke; Karlyne M Reilly
Journal:  Adv Cancer Res       Date:  2010       Impact factor: 6.242

6.  Src family kinases differentially influence glioma growth and motility.

Authors:  Laura J Lewis-Tuffin; Ryan Feathers; Priya Hari; Nisha Durand; Zhimin Li; Fausto J Rodriguez; Katie Bakken; Brett Carlson; Mark Schroeder; Jann N Sarkaria; Panos Z Anastasiadis
Journal:  Mol Oncol       Date:  2015-06-10       Impact factor: 6.603

7.  Insertional mutagenesis of preneoplastic astrocytes by Moloney murine leukemia virus.

Authors:  T A Afanasieva; V Pekarik; M Grazia D'Angelo; M A Klein; T Voigtländer; C Stocking; A Aguzzi
Journal:  J Neurovirol       Date:  2001-04       Impact factor: 2.643

Review 8.  Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.

Authors:  Manmeet S Ahluwalia; John de Groot; Wei Michael Liu; Candece L Gladson
Journal:  Cancer Lett       Date:  2010-12-08       Impact factor: 8.679

9.  Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography.

Authors:  T Kato; J Shinoda; N Nakayama; K Miwa; A Okumura; H Yano; S Yoshimura; T Maruyama; Y Muragaki; T Iwama
Journal:  AJNR Am J Neuroradiol       Date:  2008-04-03       Impact factor: 3.825

10.  Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion.

Authors:  Deborah Huveldt; Laura J Lewis-Tuffin; Brett L Carlson; Mark A Schroeder; Fausto Rodriguez; Caterina Giannini; Evanthia Galanis; Jann N Sarkaria; Panos Z Anastasiadis
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.